An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
RenovoRx to Participate in March 2022 Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company specializing in targeted cancer therapies, announced its leadership’s involvement in two investor conferences this month. The ROTH Capital Partners 34th Annual Conference will take place from March 13-15, 2022 in Dana Point, CA, with CEO Shaun Bagai presenting on March 14 at 1:30 p.m. PT. The Maxim Virtual Growth Conference occurs from March 28-30, 2022, where Bagai will present on-demand and participate in a pancreatic cancer panel on March 28. One-on-one meetings can be scheduled with the investment community.
Positive
None.
Negative
None.
LOS ALTOS, Calif.--(BUSINESS WIRE)--
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its leadership’s participation in two upcoming Investor Conferences this month.
ROTH Capital Partners 34th Annual Conference
Format and Dates: In person, March 13-15, 2022 Location:The Ritz Carlton Laguna Niguel Hotel, Dana Point, CA Presenters and Presentation Date/Time: Shaun Bagai, CEO, to present on Monday, March 14th at 1:30 p.m. PT Webcast:https://wsw.com/webcast/roth43/rnxt/1869488
Register: Visit the event website
Maxim Growth Conference Panel on Pancreatic Cancer
Format and Date: Virtual, Monday March 28, 12:00 - 1:00 pm ET Presenter:Shaun Bagai, CEO, to participate with other industry leaders on pancreatic cancer panel.
Webcast: A link to this panel will be posted to the RenovoRx Website Events page when it becomes available.
RenovoRx leadership will be available during the events for one-on-one meetings with the investment community. To schedule a meeting please reach out to your respective conference representative or by emailing KCSA Strategic Communications: RenovoRx@KCSA.com.
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx’s lead product candidate, RenovoGemTM, is a combination of gemcitabine and our patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC.
RenovoRx’s patent portfolio includes seven U.S. patents for its technology. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.
RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology.
Company Contact:
RenovoRx, Inc. Shaun R. Bagai, CEO
Christopher J. Lehman, CFO
Investor Contact:
KCSA Strategic Communications Valter Pinto or Jack Perkins T:212-896-1254
renovorx@kcsa.com
Media Contact:
Knight Marketing Communications, Ltd. Kevin Knight T: 206-451-4823
kknightpr@gmail.com
Source: RenovoRx, Inc.
FAQ
What are the dates for the ROTH Capital Partners conference for RenovoRx?
The ROTH Capital Partners 34th Annual Conference is from March 13-15, 2022.
When will Shaun Bagai present at the ROTH Capital Partners conference?
Shaun Bagai will present on March 14, 2022, at 1:30 p.m. PT.
What is the format and date for the Maxim Virtual Growth Conference?
The Maxim Virtual Growth Conference is scheduled for March 28-30, 2022, and will be conducted virtually.
How can investors schedule one-on-one meetings with RenovoRx executives?
Investors can schedule one-on-one meetings by contacting their conference representative or emailing KCSA Strategic Communications at RenovoRx@KCSA.com.
What is RenovoRx's lead product candidate?
RenovoRx's lead product candidate is RenovoGem™, which is a combination of gemcitabine and their patented delivery system, RenovoCath®.
